NEW YORK (GenomeWeb News) – BGI has partnered with GENNET, a Prague-based center for genetics, fetal medicine, and assisted reproduction, to offer its non-invasive fetal trisomy test, NIFTY, in the Czech and Slovak Republics.

The NIFTY test uses next-generation sequencing to analyze maternal plasma for fetal aneuploidies including trisomy 21, trisomy 13, and trisomy 18, which cause Down syndrome, Patau syndrome, and Edwards syndrome, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.